These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 34940089

  • 1. Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report.
    Luongo C, Porcelli T, Sessa F, De Stefano MA, Scavuzzo F, Damiano V, Klain M, Bellevicine C, Matano E, Troncone G, Schlumberger M, Salvatore D.
    Curr Oncol; 2021 Dec 16; 28(6):5401-5407. PubMed ID: 34940089
    [Abstract] [Full Text] [Related]

  • 2. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, Rassner M, Boerries M, Zielke A, la Rosee P, Meyer PT, Kroiss M, Weißenberger C, Schumacher T, Metzger P, Weiss H, Smaxwil C, Laubner K, Duyster J, von Bubnoff N, Miething C, Thomusch O.
    Thyroid; 2021 Jul 16; 31(7):1076-1085. PubMed ID: 33509020
    [Abstract] [Full Text] [Related]

  • 3. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
    Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME.
    J Immunother Cancer; 2018 Jul 11; 6(1):68. PubMed ID: 29996921
    [Abstract] [Full Text] [Related]

  • 4. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
    Soll D, Bischoff P, Frisch A, Jensen M, Karadeniz Z, Mogl MT, Horst D, Penzkofer T, Spranger J, Keilholz U, Mai K.
    BMC Endocr Disord; 2024 Feb 22; 24(1):25. PubMed ID: 38383419
    [Abstract] [Full Text] [Related]

  • 5. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM, Ryder MM, Hilger CR, Bible KC.
    Thyroid; 2017 Jul 22; 27(7):923-927. PubMed ID: 28471306
    [Abstract] [Full Text] [Related]

  • 6. Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report.
    Barbaro D, Forleo R, Profilo MA, Lapi P, Giani C, Torregrossa L, Macerola E, Materazzi G.
    Front Endocrinol (Lausanne); 2024 Jul 22; 15():1389294. PubMed ID: 39045273
    [Abstract] [Full Text] [Related]

  • 7. Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma.
    Boudin L, Morvan JB, Thariat J, Métivier D, Marcy PY, Delarbre D.
    Curr Oncol; 2022 Oct 14; 29(10):7718-7731. PubMed ID: 36290887
    [Abstract] [Full Text] [Related]

  • 8. A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib.
    Hamamoto T, Kono T, Taruya T, Ishino T, Ueda T, Takeno S.
    Auris Nasus Larynx; 2022 Jun 14; 49(3):515-519. PubMed ID: 33109426
    [Abstract] [Full Text] [Related]

  • 9. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
    Gunda V, Gigliotti B, Ashry T, Ndishabandi D, McCarthy M, Zhou Z, Amin S, Lee KE, Stork T, Wirth L, Freeman GJ, Alessandrini A, Parangi S.
    Int J Cancer; 2019 May 01; 144(9):2266-2278. PubMed ID: 30515783
    [Abstract] [Full Text] [Related]

  • 10. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.
    Kim SY, Kim SM, Kim JW, Lee IJ, Jeon TJ, Chang H, Kim BW, Lee YS, Chang HS, Park CS.
    Front Endocrinol (Lausanne); 2020 May 01; 11():599. PubMed ID: 32982983
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
    Di Desidero T, Orlandi P, Gentile D, Banchi M, Alì G, Kusmic C, Armanetti P, Cayme GJ, Menichetti L, Fontanini G, Francia G, Bocci G.
    Pharmacol Res; 2020 Aug 01; 158():104920. PubMed ID: 32461187
    [Abstract] [Full Text] [Related]

  • 12. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
    Adam P, Kircher S, Sbiera I, Koehler VF, Berg E, Knösel T, Sandner B, Fenske WK, Bläker H, Smaxwil C, Zielke A, Sipos B, Allelein S, Schott M, Dierks C, Spitzweg C, Fassnacht M, Kroiss M.
    Front Endocrinol (Lausanne); 2021 Aug 01; 12():712107. PubMed ID: 34475850
    [Abstract] [Full Text] [Related]

  • 13. Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience.
    Park J, Jung HA, Shim JH, Park WY, Kim TH, Lee SH, Kim SW, Ahn MJ, Park K, Chung JH.
    Eur J Endocrinol; 2021 May 06; 184(6):837-845. PubMed ID: 33852431
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE).
    Higashiyama T, Sugino K, Hara H, Ito KI, Nakashima N, Onoda N, Tori M, Katoh H, Kiyota N, Ota I, Suganuma N, Hibi Y, Nemoto T, Takahashi S, Yane K, Ioji T, Kojima S, Kaneda H, Sugitani I, Tahara M.
    Eur J Cancer; 2022 Sep 06; 173():210-218. PubMed ID: 35932627
    [Abstract] [Full Text] [Related]

  • 15. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
    Takahashi S, Tahara M, Ito K, Tori M, Kiyota N, Yoshida K, Sakata Y, Yoshida A.
    Adv Ther; 2020 Sep 06; 37(9):3850-3862. PubMed ID: 32676927
    [Abstract] [Full Text] [Related]

  • 16. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview.
    Sparano C, Godbert Y, Attard M, Do Cao C, Zerdoud S, Roudaut N, Joly C, Berdelou A, Hadoux J, Lamartina L, Schlumberger M, Leboulleux S.
    Endocr Relat Cancer; 2021 Jan 06; 28(1):15-26. PubMed ID: 33112817
    [Abstract] [Full Text] [Related]

  • 17. Boosted abscopal effect from radiotherapy and pembrolizumab in anaplastic thyroid cancer: a mini-review and case report.
    Goh D, Lim KH, Sudirman SRB, Ang MK, Chua MLK, Lim CM.
    Chin Clin Oncol; 2023 Oct 06; 12(5):57. PubMed ID: 37964542
    [Abstract] [Full Text] [Related]

  • 18. Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer.
    Yamazaki H, Yokose T, Hayashi H, Iwasaki H, Osanai S, Suganuma N, Nakayama H, Masudo K, Rino Y, Masuda M.
    Cancer Chemother Pharmacol; 2018 Oct 06; 82(4):649-654. PubMed ID: 30051190
    [Abstract] [Full Text] [Related]

  • 19. Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma.
    Osawa Y, Gozawa R, Koyama K, Nakayama T, Sagoh T, Sunaga H.
    Intern Med; 2018 Apr 01; 57(7):1015-1019. PubMed ID: 29225265
    [Abstract] [Full Text] [Related]

  • 20. Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice.
    Wang R, Yamada T, Arai S, Fukuda K, Taniguchi H, Tanimoto A, Nishiyama A, Takeuchi S, Yamashita K, Ohtsubo K, Matsui J, Onoda N, Hirata E, Taira S, Yano S.
    Mol Cancer Ther; 2019 May 01; 18(5):947-956. PubMed ID: 30926637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.